Paradigm Biocapital Advisors LP Ascendis Pharma A/S Transaction History

Paradigm Biocapital Advisors LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $18.9 Million - $24 Million	156,355 Added 30.78%	664,307 $90.6 Million
Q1 2024 May 15, 2024	BUY	$123.45 - $159.4 $19.3 Million - $24.9 Million	156,252 Added 44.43%	507,952 $76.8 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $30.3 Million - $44.8 Million	351,700 New	351,700 $44.3 Million
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $203,715 - $246,206	-1,942 Reduced 0.55%	350,866 $37.6 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $14.4 Million - $19.1 Million	-144,539 Reduced 29.06%	352,808 $43.1 Million
Q3 2022 Nov 14, 2022	BUY	$84.03 - $110.23 $5.48 Million - $7.18 Million	65,177 Added 15.08%	497,347 $51.4 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $8.63 Million - $13 Million	110,549 Added 34.37%	432,170 $40.2 Million
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $10.6 Million - $14 Million	103,463 Added 47.43%	321,621 $37.7 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $27.7 Million - $37 Million	218,158 New	218,158 $29.3 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Paradigm Biocapital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Paradigm Biocapital Advisors LP with notifications on news.